Litigation Windfall Driving Roivant Sciences' Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) [Yahoo! Finance]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Yahoo! Finance
million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant's US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully shape Roivant's reported profitability. Next, we'll examine how the large Genevant–Moderna settlement reshapes Roivant's pre-existing investment narrative built around late-stage pipeline milestones. Find 48 companies with promising cash flow potential yet trading below their fair value Roivant Sciences Investment Narrative Recap To own Roivant Sciences today, you need to believe that its late stage autoimmune and cardiopulmonary pipeline, led by brepocitinib and IMVT-1402, can eventually support a sustainable commercial business despite currently modest sales and ongoing losses. The Genevant–Moderna litigation gain has temporarily b
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Nomura Healthcare Fund Q1 2026 Commentary [Seeking Alpha]Seeking Alpha
- Baron Health Care Fund Q1 2026 Shareholder Letter [Seeking Alpha]Seeking Alpha
- Roivant Sciences (ROIV) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- TD Cowen Raises its Price Target on Roivant Sciences (ROIV) [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d)" to "sell (d-)".MarketBeat
ROIV
Earnings
- 5/20/26 - Beat
ROIV
Sec Filings
- 5/22/26 - Form 4
- 5/22/26 - Form 4
- 5/22/26 - Form 144
- ROIV's page on the SEC website